Table C34

KQ1 Outcome V. Tumor Response: Darbepoetin versus Control

Study IDOutcomeIntervention Events/sample sizeControl Events/sample sizeHazard ratio (95% CI)P valueSource & comments
Vansteenkiste 2002 Number progressed during study or follow up94/155110/159
  • 1) HR 0.70 (0.53; 0.92)
  • 2) HR 0.71 (0.54, 0.94)
NRFDA report, 12 months median follow up;
  • 1) Cox proportional hazard, treatment group as independent variable
  • 2) adjusted for tumor type and region
Vansteenkiste 2002 Progression free survival (disease progression or death)131/155145/159HR 0.81 (0.64; 1.03)NRAmgen presentation (FDA ODAC), adjusted for histology, 24 months follow up

From: Appendix C, Evidence Tables

Cover of Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment [Internet].
Comparative Effectiveness Reviews, No. 3.
Seidenfeld J, Piper M, Bohlius J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.